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ABSTRACT
In 2006 Momčilović et al. measured radioacvity levels of 210Po and 210Bi by - and -measurements
resp. to determine the natural distribuon of environmental radon daughters in the different brain
areas of an Alzheimer Disease vicm. We show that -ray spectrometry of the mother nucleus 210Pb
can be used. It is a direct measurement without tampering with the sample. However, because this
technique is far less sensive than - and -spectrometry,  acvity values previously published were
out-of-reach for  -ray spectrometry. This is no longer the case with our ultra-low background high-
purity  Ge  detectors  which  have  been  developed  in  the  frame  of  the  neutrino  experiments.  To
ascertain this possibility, ten brain samples from Alzheimer paents and blanks as well as 10 samples
of  brain  tumors  have  been  invesgated  and  results  were  cross-checked  with  two  different
spectrometers. Localizaon of the samples in the brain was not known to avoid biased interpretaon
of the results. Data taking lasted between 1 and 4 weeks for each sample. All ten Alzheimer/blank
samples were below the limit of detecon (LOD), 3 out of the 10 tumors lead to posive results (3.8 to
4.9 mBq/g of 210Pb) with a stascal significance of at least 3 standard deviaons. Potenal followup of
this  method  is  to  enhance  the  detector  sensivity,  having  the  spectrometer  installed  in  an
underground laboratory such as the one in Modane under the Alps where the background noise is 30-
fold less than at the present locaon in Bordeaux. The final aim is to map a brain in collaboraon with
Alzheimer/Parkinson experts.
INTRODUCTION
In our environment, natural acvity stems from the presence of several radioacve nuclei,  among
which the isotopes of Uranium (238U,  235U), Thorium (232Th) and their progeny, as well as Potassium
(40K). All these nuclei have decay half-lifes of the order of a billion years which are close to Earth's age.
Our study focuses on the 238U decay chain (half-life = 4.5×109 years). Figure 1 shows the decay process
from 238U all the way through 206Pb, a stable isotope.
Figure 1: 238U, one of the three natural radioac-vity families
238U is found mainly in rocks and soils with a radioacve intensity around a few tens of Bq/kg. One of
its progeny is  226Ra (Half-life = 1,600 years), a highly soluble element. Because of this property, it is
found almost everywhere in nature at varying acvity levels.  This isotope is an alpha emiGer and
transforms to the well-known gaseous and radioacve Radon-222 (222Rn) with a 3.8 day half-life. Being
a neutral gas, it migrates from the rocks and soils to the atmosphere leading to Radon levels in the air
ranging from a few Bq/m3 to several thousands of Bq/m3 in confined places like underground mining
areas.
Radon-222  is  also  an  alpha  emiGer  and  gives  Polonium-218  (218Po)  in  a  posively  charged  state.
Because it is ionized, it scks on aerosols and/or dust parcles present in the air.  218Po and progeny
half-lifes are very short and the decay processes lead rapidly to Lead-210 (210Pb) which has a half-life of
22 years, comparable to human life expectancy. 
Earth gravity and rain precipitate 210Pb to the ground and over all that is growing. We have measured
210Pb acvity in vine and oak tree leaves (around 100 Bq/kg dry weight),  in fruit skins mainly from
apples and peaches, in tobacco leaves (a few Bq/kg dry weight) and in seafood (high levels of  210Pb
because of the presence of radium in water which is connuously filtered by the living organisms).
Lead-210 enters living organisms through breathing,  eang and drinking.  The amount is  very  low,
however it is measurable by today's “low background level gamma spectrometers” like those from our
research group, capable of measuring acvies 3 to 4 magnitudes lower than the natural ambient
level.
The human body rejects most of the ingested acvity through natural processes, but some is leK in
the body, mostly in bones (around 2 Bq/kg), partly in soK ssues like liver, kidneys, lungs and muscles
(around 0.2 Bq/kg).  210Pb is  a  quite harmless isotope:  it  is  a  beta  emiGer  of  low energy radiaon
(Qβ = 63 keV), negligible compared to beta radiaon from 40K and 14C, two isotopes naturally present in
the human body at levels of some tens of Bq/kg. However  210Pb decays to Polonium-210 (210Po), an
alpha emiGer with sufficient energy (Eα = 5.3 MeV) to damage DNA. Ingested at huge radioacvity
levels of the order of 1 GBq, 210Po is lethal within a few weeks as in the famous case of the poisoning
of Alexander V. Litvinenko.  210Po is even more radiotoxic than Plutonium:  1 µg [210Po] = 0.16 Gbq =
14 kg [238U].
Figure 2: radioac-vity of 210Bi and 210Po inside the brain measured by  Momčilović on a cohort of
more than 30 pa-ents suffering from Alzheimer or Parkinson diseases, smokers and non-smokers.
Radioac-vity of 210Bi and 210Po inside the brain
Numerous data compilaons on the radioacvity levels in different parts of the human body are at
hand. However, we are aware of only a single research team that has worked on the distribuon of
210Po in the brain. In a 1999 published work, pursued in 2001, Momčilović et al. showed:
1/ the presence of radon progeny in human brains,
2/  that  the  acvity  levels  were  at  least  10  mes greater  for  brains  from Alzheimer  or  Parkinson
paents (even larger values were obtained for some smoker paents) than for control/blank brains,
3/ the accumulaon of  210Bi/210Po was not uniform in the brains, but seemingly dependent on the
disease,
4/ the same distribuons for 210Po (alpha measurement) and 210Bi (beta measurement) which implies
the presence of their mother nucleus 210Pb.
Figure 2, which shows graphically those results, is reproduced from their paper.
In a second paper from 2006 following an oral communicaon in a conference in 2003, the same
research team measured 210Po in different parts of a single old woman with Alzheimer Disease (AD),
who passed away at 86 years of age.  The observed acvies are very weak, they range from 0.2 to
2 mBq for a 1 g sample, as shown in Figure 3, which comes from their paper.
Fortunately, 210Pb “regular” ingeson is only a few Bq on a daily basis. Nonetheless, and that is what
triggered our concern, this is an on-going process all along one's life. What are the long-term effects
on our health?
Figure 3: very fine analysis by  Momčilović and al of the different parts of the brain of a deceased old
woman, suffering from AD. Added to the original drawing are the LOD for our gamma-ray
spectrometers at the PRISNA facility for bot a 1 g and a 6 g sample a a 1 week measurement.
EXPERIMENTAL
How to detect and measure 210Pb and its progeny (210Bi and 210Po)?
There are several ways to reveal the presence of 210Pb in a given sample. The pioneering one relies on
the  chemical  separaon of  210Po  followed  by  alpha  spectrometry.  This  a  very  sensive  technique
yielding  results down to 0.1 mBq/g even with samples weighing less than a gram. The drawback is
that the sample is destroyed and that the protocol demands a second measurement aKer a waing
period  of  2  years  to  check  if  the  secular  equilibrium between  mother  and  daughter  nuclei  was
reached. On top of this, one needs radioacve tracers (208Po or 209Po) which, nowadays, are difficult to
obtain.
A second way is also a chemical separaon, this me of 210Bi, followed by liquid scinllaon for beta
spectrometry.  The  sensivity  is  roughly  the  same  as  in  the  previous  method,  the  protocol  is
complicated and the sample is destroyed. However, because of much shorter periods (half-lifes), the
secular equilibrium is reached much quickly in this case (1-2 months instead of 2 years).
The third and last possibility: measure directly the 46 keV gamma-ray emiGed by  210Pb with a “low
background noise gamma spectrometer”. The advantages are three-fold: 1) no tampering with the
sample which remains intact for further analysis and/or in case of a valuable specimen, 2) very light
handling of the sample, 3) no need for a second measurement, data acquired is readily obtained and
usable. 
Figure 4: 210Pb decay scheme
The only weak point compared to the two precedent techniques is that the measurement sensivity is
somewhat lower (around 1 mBq/g for a few grams of sample and one week data acquision with our
gamma spectrometers at the PRISNA1 facility). This is due to the weak gamma-ray branching rao for
the 46 keV line (only 4.25% probability of decaying via the emission of a gamma ray). The paral decay
scheme for 210Pb is shown in Figure 4.
In Figure 3, we have added our experimental sensivity (vercal green doGed lines) for a 300 cm3 Ge
1 PRISNA is a semi-underground facility, partially shielded from cosmic ray interactions and natural radioactivity, 
located on the premises of the CENBG institute in Gradignan
(Germanium) detector of “well type”. This sensivity depends on the sample mass and the duraon of
data acquision: 3 mBq/g for a 1 g sample and 0.5 mBq/g for a 6 g sample. This means that we could
have had posive results with the samples measured a decade earlier by  Momčilović et al and this
comforted us to get in touch with the La Pié-Salpêtrière hospital in Paris, France for a first set of
measurements and proof of feasibility.
RESULTS & DISCUSSION
Brain samples received weighed around 1 g and were condioned either with or without formalin in
sealed 5 cm3 cylindrical polyethylene tubes. These tubes fit exactly the “well” part of our gamma-ray
spectrometers.
Each sample was measured for 1 to more than 3 weeks to minimize stascal uncertaines. Since this
was a proof-of-feasibility experiment, we cross-checked the data by performing dual measurements
on a second detector in order to ascertain that the observed radiaon was not inherent to a specific
spectrometer.  For  the  46 keV  line,  the  detector's  efficiency  is  60%  with  an  energy  resoluon
(FWHM/Full Width Half Maximum) of 2 keV.
Figure 5: graphical representa-on of all measurements from Table 1. Limit of detec-on (LOD) is
around 3 mBq/g for a 1 g sample and a one week data acquisi-on.
We did not have informaon on the samples that were sent. Especially, no clue was given as to which
part of the brain they stemmed from.
Two series were obtained.  The first one, marked as A07-xxx to A12-xxx included 5 “blank” and 5
“Alzheimer” samples.  They were condioned with formalin in the polyethylene tubes. The second
series,  noted  N13-xxx,  originated  from  paents  with  different  types  of  brain  tumors.  They  were
condioned without formalin. The samples weighed between 0.77 g and 1.84 g. 
Table 1 lists the samples and the measurements data. Figure 5 is a graphical representaon of the
results.  All  the  Axx.xxx samples  lead  to  a  detecon limit  of  around 2 to 3  mBq/g.  Two of  those
samples,  A007-0063  and  A10-2006,  were  also  measured  at  the  LSM  (Laboratoire  Souterrain  de
Modane under the Alps), but only for one week each. The results were also limit values, resp. < 0.61
and < 0.77 mBq/g with a sensivity threshold 5 mes beGer than in PRISNA, thanks to beGer shielding
due to thousands of feet of rock which lowers the background by a factor 30 compared to PRISNA. 
With the N13-xxx series, 7 samples were also at the detecon limit (values between 1.7 and 3.4 mBq/
g,  depending on sample  mass  and  measurement  duraon).  Most  interesng  were the  measured
posive values for 3 samples, between 3.8 and 4.9 mBq/g, with a stascal significance of at least 3
standard deviaons. 
From Figure 5 one infers that the detecon limit in PRISNA is around 3 mBq/g for a 1 g sample and a
one week data acquision. 
CONCLUSIONS
This preliminary study confirmed that today's sensivity of the gamma spectrometers in PRISNA is
good enough to measure 210Pb in brain samples originang from the natural radioacvity. At this stage
of the study, lack of knowledge of the precise localizaon in the brain of the samples prevents us from
associang our results with a pathology.
Upcoming improvements are:
1/ enhance the detector sensivity with a new “well type” Ge gamma-ray spectrometer of a smaller
volume  (100 cm3 instead  of  300 cm3),  which  decreases  the  interfering  high  energy  gamma  ray
contribuon (Compton effect) and has excellent resoluon (1 keV at 46 keV) with the same efficiency
(60% at 46 keV). 
2/ have the spectrometer installed at LSM in the underground laboratory with a 30-fold decrease in
background noise.
Last but not least, se^ng up and broadening a collaboraon with Alzheimer/Parkinson specialists.
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Table 1: list of samples, measurement dura-on (days), sample weight, values obtained or limits 
(marked by *) for 210Pb (mBq/g). All measurements done at the PRISNA facility in Gradignan (Bordeaux
sample ID weight (g)
A
L
Z
H
E
IM
Z
E
R
PRISNA
A07-0063
10.9
1.14
2.3*
LSM 6.5 0.6*
PRISNA
A08-992 10.3 1.38 2.1*
A09-606 8.0 1.00 2.8*
A10-766 7.6 0.99 2.7*
A10-1848 8.9 1.84 1.4*
PRISNA
A10-2006 
12.2
0.91
2.3*
LSM 6.5 0.8*
PRISNA
A11-1620 8.0 1.00 3.2*
A11-2051 7.1 1.09 2.7*
A12-129 7.9 1.30 2.1*
A12-1966 8.4 1.23 2.2*
T
U
M
O
R
S
PRISNA
N13-366 20.7 0.77 2.0*
N13-369 33.2 1.50 0.6*
N13-383 7.0 1.63 1.8*
N13-396 13.9 1.08 2.0*
N13-418 21.0 1.45 1.9*
N13-439 9.0 1.34 1.7*
N13-455 14.0 0.83 4.9 (1.3)
N13-470 21.0 0.95 3.8 (1.0)
N13-488 22.1 0.90 4.8 (1.5)
N13-518 10.9 0.92 1.8*
spectrometer 
locaon
measurement 
duraon (days)
acvity (mBq/
g)
suburb). Two samples were measured at both PRISNA and the LSM (Laboratoire Souterrain de 
Modane), a laboratory in a road tunnel between Italy and France, under the Alps. 
